Site Search
Displaying results 351 - 360 of 573
Resource | Fact Sheets,
Of the estimated 810 000 PLHIV, an estimated 46.9% contracted HIV through heterosexual contact, 20.3% through male‐to‐male sex, 25.7% through injecting drug use, 6.0% through former plasma donation or receipt of contaminated blood/blood products, and 1.1% through mother to child transmission (MTCT). There are significant increases in MSM transmission.
Resource | Publications,
The UNAIDS report Fast-Track: Ending the AIDS Epidemic by 2030 outlines that by taking the Fast-Track approach nearly 28 million new HIV infections and 21 million AIDS-related deaths would be averted by 2030.
Resource | Publications,
The paper provides information on the prices paid by 20 middle-income countries for adult and paediatric formulations of antiretroviral treatments recommended by WHO. It links this information with an analysis of the intellectual property situation of the selected medicines taking into account existing license agreements as well as compulsory licenses, and includes data and general information on a number of other determinants of prices and availability of ARVs, including tariffs, markups and taxes, as well as the regulatory status.
Resource | Publications,
Fast-tracking the AIDS response and setting ambitious targets are critical to ending the AIDS epidemic. This requires transforming the vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths into concrete milestones and endpoints.
Resource | Publications,
Vietnam has a concentrated HIVepidemic, with the highest HIV prevalence being observed among people who inject drugs (PWID). Based on its experience scaling-up robust HIV interventions, Vietnam aims to further strengthen its response by harnessing the preventive benefits of antiretroviral therapy (ART).
Resource | Publications,
In the Trans Pacific partnership Agreement (TPPA) negotiations, the United States has proposed expanded patent protections that will likely impact the affordability of medicines in TPPA partners. This includes antiretroviral (ARV) medicines used in the treatment of HIV/AIDS. Vietnam has the lowest GDP per capita of the 12 countries participating in the TPPA negotiations. Using the current Vietnamese patent regime as our base case, we analyse the potential impact of alternative patent regimes on access to ARVs in Vietnam.
Resource | Laws and Policies,
This guideline is developed to ensure safe and effective use of Antiretroviral therapy (ART) for people living with human immunodeficiency virus (PLHIV). It is a local adaptation of the WHO Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection released in June 2013.
Resource | Publications,
This 17th edition of Untangling the Web of Antiretroviral Price Reductions is a departure from recent previous years. For this edition, the methods of collecting information on the sources and prices of antiretrovirals (ARVs) remain the same, but information is presented in a new, shorter format focusing on a few key drugs as well as future regimens, along with an analysis of the current opportunities, challenges and threats faced in keeping the price of ARVs down.
Resource | Publications,
This report has been compiled using country-level data reported to WHO on the procurement of ART via the Global Procurement Reporting Mechanism (GPRM), the WHO database on the regulatory status of ART, reports on the production capacity for the active pharmaceutical ingredients (APIs) of ARVs, the annual WHO surveys on the use of ART, the Global AIDS Response Progress Report data, the Global Update on the Health Sector Response to HIV 2014, as well as contributions from countries and major stakeholders involved in ART access.
In this report we examine global trends in ARV prices and assess how WHO treatment guidelines have influenced the uptake of different ARV formulations.